Sihuan Pharmaceutical Holdings Group Ltd

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Kaken Obtains Aadi’s Fyarro, Comm

Initial public offerings (IPOs) for innovative, drug-focused biotechs have remained elusive in the Chinese mainland well into the second half of 2024, since the country’s top securities regulator put

Novartis AG ’s CDK4/6 inhibitor Kisqali has reduced risk of disease recurrence in the pivotal NATALEE trial in early breast cancer (EBC) patients, with positive data in the intermediate-risk populatio

Mega funding deals recently returned to Chinese bioventures developing small molecule drugs, as investors seemingly reignited their enthusiasm for such companies. Reistone Biopharma Company Limited ,